| 43rd week of 2012 patent applcation highlights part 45 |
| Patent application number | Title | Published |
|---|
| 20120270744 | METHODS TO DETERMINE IF A SUBJECT WILL RESPOND TO A BCR-ABL INHIBITOR - Methods are provided for determining if a subject of interest will respond to treatment with BCR-ABL inhibitor, comprising. The method includes quantitating expression of a plurality of genes in CD34+ cells isolated from the subject. Expression of the plurality of genes in the subject of interest is compared to a control. Altered expression of the plurality of genes in as compared to the control indicates that the subject of interest will respond to treatment with the BCR-ABL inhibitor. Arrays are also provided. | 2012-10-25 |
| 20120270745 | DRUG SELECTION FOR CANCER THERAPY BY PROFILING SIGNAL TRANSDUCTION PROTEINS IN ASCITES OR PLEURAL EFFLUX SAMPLES - The present invention provides methods for selecting a suitable anticancer therapy and for identifying and predicting response for the treatment of a gastric cancer by determining the expression level and/or activation level of one or more analytes in a cell such as a cancer cell from an ascites sample. The present invention also provides methods for selecting a suitable anticancer therapy and for identifying and predicting response for the treatment of a lung cancer such as a non-small cell lung cancer by determining the expression level and/or activation level of one or more analytes in a cell such as a cancer cell from a pleural efflux sample. | 2012-10-25 |
| 20120270746 | CANCER MARKER, METHOD FOR EVALUATION OF CANCER BY USING THE CANCER MARKER, AND EVALUATION REAGENT - The present invention provides a novel cancer marker for evaluating the onset, the preclinical stage, the clinical stage, or the prognosis of a cancer in a subject, and an evaluation method using the same. A cancer marker containing at least one miRNA selected from hsa-miR-92 and hsa-miR-494 is used as a marker for cancers excluding breast cancer. A method for evaluating the possibility of cancers excluding breast cancer includes the step of detecting the expression level of a cancer marker in a biological sample collected from a subject. In this method, the cancer marker contains at least one miRNA selected from hsa-miR-92 and hsa-miR-494. | 2012-10-25 |
| 20120270747 | METHOD OF PREDICTING RISK OF PRE-TERM BIRTH - A method for diagnosing, or differentially diagnosing, an increased risk of pre-term birth (PTB) involves detecting or measuring increased expression of a biomarker Soluble E-cadherin (SE-CAD) in a biological sample from a mammalian subject, particularly in the urine, cervicovaginal fluid or blood. An increased level of expression of SE-CAD above the level of expression in the same sample of a healthy mammalian subject is an indication of a diagnosis of increased risk of PTB. Such diagnosis may further involve identify other clinical symptoms of PTB or PTL. Additionally the method may use additional biomarkers, such as fetal fibronectin. | 2012-10-25 |
| 20120270748 | PEPTIDE DISPLAY ARRAYS - The present invention provides arrays, methods of constructing arrays, and methods of use of such arrays. The arrays of the invention comprise a substrate with two or more discrete constructs or discrete sets of constructs associated on the surface of the substrate, optionally via a linker molecule. The constructs include an oligonucleotide comprising a region encoding a peptide of interest and an affinity tag and an untranslated region, a fusion peptide comprising both the peptide of interest and the affinity tag and a capture agent that forms a binding pair with the affinity tag. | 2012-10-25 |
| 20120270749 | METHODS AND USES RELATING TO THE IDENTIFICATION OF COMPOUND INVOLVED IN PAIN AS WELL AS METHODS OF DIAGNOSING ALGESIA - The present invention relates to a method of identifying a compound involved in pain, the use of C1qb nucleic acid or C1qb protein for identifying a compound involved in pain as well as methods of diagnosing algesia involving the same. | 2012-10-25 |
| 20120270750 | Microarray Synthesis and Assembly of Gene-Length Polynucleotides - There is disclosed a process for in vitro synthesis and assembly of long, gene-length polynucleotides based upon assembly of multiple shorter oligonucleotides synthesized in situ on a microarray platform. Specifically, there is disclosed a process for in situ synthesis of oligonucleotide fragments on a solid phase microarray platform and subsequent, “on device” assembly of larger polynucleotides composed of a plurality of shorter oligonucleotide fragments. | 2012-10-25 |
| 20120270751 | siRNA Targeting Diacylglycerol O-Acyltransferase Homolog 2 (DGAT2) - Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for DGAT2. | 2012-10-25 |
| 20120270752 | ANALYZING THE EXPRESSION OF BIOMARKERS IN CELLS WITH MOMENTS - Cell profile data is stored. The cell profile data comprises multiplexed biometric images capturing the expression of a plurality of biomarkers by at least one tissue sample from a patient with respect to at least one field of view. Individual cells are delineated and segmented into compartments. At least one cell feature is calculated based on the cell's expression of each of a plurality of biomarkers. A first moment is calculated for each cell feature. The moments are examined for an association with a diagnosis, a prognosis of a response to treatment of a condition or disease. Apparatus for performing the foregoing steps are disclosed. | 2012-10-25 |
| 20120270753 | METERING DEVICE AND METHOD FOR OPERATING SAME - A metering device, a metering element, and a method for operating same, the metering element having a storage container open on one side for receiving the substances to be metered and a plunger which is axially movable and reversibly seals the opening of the storage container and which preferably has at least one centrally located metering opening for metering the substances provided in the storage container, the plunger including a separation device for particles. | 2012-10-25 |
| 20120270754 | Iterative Nucleic Acid Assembly Using Activation of Vector-Encoded Traits - Certain aspects of the present invention provide methods for assembling nucleic acid molecules using iterative activation of one or more vector-encoded traits to progressively assemble a longer nucleic acid insert. Aspects of the invention also provide kits, compositions, devices, and systems for assembling synthetic nucleic acids using iterative activation of one or more vector-encoded traits. | 2012-10-25 |
| 20120270755 | METHOD FOR PREPARING A SUBSTRATE FOR ARRANGING ANIMAL CELLS IN AN ARRAY AND METHOD FOR PREPARING A SUBSTRATE ON WHICH ANIMAL CELLS ARE ARRANGED IN AN ARRAY - A new means of separately arranging individual animal cells on a substrate surface is provided. A method for preparing a substrate for arranging animal cells in an array, comprising steps (1) to (3): (1) preparing a substrate having adsorption surfaces in an array on an electrode substrate surface; (2) causing an extracellular matrix to adsorb to the electrode surface and the adsorption surfaces of the substrate; and (3) applying a weak potential to the electrode to cause the extracellular matrix on the electrode surface to separate to obtain a substrate with the extracellular matrix adhered to the adsorption surfaces thereof. A method for preparing a substrate on which animal cells have been arranged in an array, comprising steps (1) to (4): (1) preparing a substrate having adsorption surfaces in an array on an electrode substrate surface; (2) causing an extracellular matrix to adsorb to the electrode surface and the adsorption surfaces of the substrate; (3) applying a weak potential to the electrode to cause the extracellular matrix on the electrode surface to separate to obtain a substrate with extracellular matrix adhered to the adsorption surfaces thereof; and (4) culturing the animal cells on the surface of the substrate obtained in (3) to obtain a substrate on which the animal cells have adhered to the adsorption surface. | 2012-10-25 |
| 20120270756 | FORMATION OF IMMOBILIZED BIOLOGICAL LAYERS FOR SENSING - The invention is directed to enzyme immobilization compositions comprising: one or more enzymes, a humectant, an acrylic-based monomer, a water-soluble organic photo-initiator and a water-soluble acrylic-based cross-linker in a substantially homogeneous aqueous mixture. The invention is also directed to methods for forming sensors comprising such compositions and to apparati for forming arrays of immobilized layers on an array of sensors by dispensing such compositions onto a substrate. | 2012-10-25 |
| 20120270757 | SITE-SPECIFIC LABELING OF AFFINITY TAGS IN FUSION PROTEINS - The present invention provides methods and fluorescent compounds that facilitate detecting and labeling of a fusion protein by being capable of selectively binding to an affinity tag. The fluorescent compounds have the general formula A(B)n, wherein A is a fluorophore, B is a binding domain that is a charged chemical moiety, a protein or fragment thereof and n is an integer from 1-6 with the proviso that the protein or fragment thereof not be an antibody or generated from an antibody. The present invention provides specific fluorescent compounds and methods used to detect and label fusion proteins that contain a poly-histidine affinity tag. These compounds have the general formula A(L)m(B)n wherein A is a fluorophore, L is a linker, B is an acetic acid binding domain, m is an integer from 1 to 4 and n is an integer from 1 to 6. | 2012-10-25 |
| 20120270758 | Degradable Surfactants, Including Degradable Gemini Surfactants, and Associated Methods - A subterranean treatment fluid comprising a degradable gemini surfactant composition described by the following formula: | 2012-10-25 |
| 20120270759 | METHODS AND COMPOSITIONS FOR ENHANCING GUAR HYDRATION RATES AND PERFORMING GUAR DERIVATIZATION REACTIONS - Methods are provided that include, but are not limited to, methods of treating guar splits comprising: exposing guar splits to a treatment chemical to create treated guar splits, wherein the treatment chemical comprises at least one treatment chemical selected from the group consisting of: an aqueous salt solution; a caustic solution, and a derivatizing agent; and grinding the treated guar splits to create ground, treated guar splits. | 2012-10-25 |
| 20120270760 | Boron Crosslinkers For Fracturing Fluids With Appreciably Lower Polymer Loading - Fracturing fluid compositions and methods of fracturing subterranean formations using polyboronic compounds as crosslinking agents are provided. The compositions and methods of the present invention allow for lower polymer loadings because achieving higher fracturing fluid viscosities can be achieved using less polymer than in traditional crosslinked systems. | 2012-10-25 |
| 20120270761 | SLIDING MEMBER | 2012-10-25 |
| 20120270762 | GREASE COMPOSITION - There is provided a grease composition, in which a grease film on the surface of the applied part is made thicker compared with conventional grease compositions, this thickness is maintained for a long period of time, and as a result, a longer service life against seizure compared with conventional grease compositions is assured. The grease composition comprises a base oil and a thickener, wherein the thickener is a diurea compound obtained by allowing an amine mixture comprising alkylphenylamine, an alkyl group of which has 8 to 16 carbon atoms, and cyclohexylamine, to react with a diisocyanate compound, and an amount of cyclohexylamine in the total amount of the alkylphenylamine and cyclohexylamine is from 91 to 99% by mole. | 2012-10-25 |
| 20120270763 | SPIN-ON FORMULATION AND METHOD FOR STRIPPING AN ION IMPLANTED PHOTORESIST - A spin-on formulation that is useful in stripping an ion implanted photoresist is provided that includes an aqueous solution of a water soluble polymer containing at least one acidic functional group, and at least one lanthanide metal-containing oxidant. The spin-on formulation is applied to an ion implanted photoresist and baked to form a modified photoresist. The modified photoresist is soluble in aqueous, acid or organic solvents. As such one of the aforementioned solvents can be used to completely strip the ion implanted photoresist as well as any photoresist residue that may be present. A rinse step can follow the stripping of the modified photoresist. | 2012-10-25 |
| 20120270764 | SULFOMETHYLSUCCINATES, PROCESS FOR MAKING SAME AND COMPOSITIONS CONTAINING SAME - Sulfomethylsuccinates of the formula: | 2012-10-25 |
| 20120270765 | LAUNDRY SCENT ADDITIVE - A laundry scent additive having polyethylene glycol and perfume. The laundry scent additive enables consumers to control the amount of scent imparted to their laundry. | 2012-10-25 |
| 20120270766 | EARLY PROGRAMMING OF BRAIN FUNCTION THROUGH SOY PROTEIN FEEDING - Disclosed are methods for improving memory and/or cognition in an infant by administering soy protein to the infant's mother during pregnancy, and further administering soy protein to the infant after delivery. The soy protein may be administered to the infant's mother during lactation if the infant is breastfed and/or may be directly administered, for example, by administering the infant an infant and/or nutritional formula comprising soy protein. Also disclosed are compositions comprising soy protein that may be used in the methods. | 2012-10-25 |
| 20120270767 | Tumor Activated Prodrugs - The instant invention provides compositions comprising a prodrug, the prodrug comprising a therapeutically active drug; and a peptide selected from the group consisting of the sequences: Ser-Ser-Lys-Tyr-Gln (SEQ ID NO:1); Gly-Lys-Ser-Gln-Tyr-Gln (SEQ ID NO:2); and Gly-Ser-Ala-Lys-Tyr-Gln (SEQ ID NO:3) wherein the peptide is linked to the therapeutically active drug to inhibit the therapeutic activity of the drug, and wherein the therapeutically active drug is cleaved from the peptide upon proteolysis by an enzyme having a proteolytic activity of prostate specific antigen (PSA). The invention further provides methods of making and using the claimed compositions. | 2012-10-25 |
| 20120270768 | Tumor Activated Prodrugs - The instant invention provides compositions comprising a prodrug, the prodrug comprising a therapeutically active drug; and a peptide selected from the group consisting of the sequences: Ser-Ser-Lys-Tyr-Gln (SEQ ID NO:1); Gly-Lys-Ser-Gln-Tyr-Gln (SEQ ID NO:2); and Gly-Ser-Ala-Lys-Tyr-Gln (SEQ ID NO:3) wherein the peptide is linked to the therapeutically active drug to inhibit the therapeutic activity of the thug, and wherein the therapeutically active drug is cleaved from the peptide upon proteolysis by an enzyme having a proteolytic activity of prostate specific antigen (PSA). The invention further provides methods of making and using the claimed compositions. | 2012-10-25 |
| 20120270769 | METHODS OF USING MACROCYCLIC INHIBITORS OF SERINE PROTEASE ENZYMES - The present invention relates to novel macrocyclic compounds and salts thereof that bind to and/or are inhibitors of serine protease enzymes and methods of using the compounds. The present invention also relates to intermediates of these compounds, pharmaceutical compositions containing these compounds and methods of using the same. These compounds are useful as therapeutics for treatment and prevention of a range of disease indications including hyperproliferative disorders, in particular those characterized by tumor metastasis, inflammatory disorders, skin and tissue disorders, cardiovascular disorders, respiratory disorders and viral infections. | 2012-10-25 |
| 20120270770 | Anti-angiogenic peptides and their uses - This invention relates to novel synthetic lytic peptide fragments of full-length peptides with the capacity to modulate angiogenic activity in mammals. The invention also relates to the use of such peptides in pharmaceutical compositions and in methods for treating diseases or disorders that are associated with angiogenic activity. | 2012-10-25 |
| 20120270771 | APOLIPOPROTEIN A-1 MIMIC PEPTIDES, AND THERAPEUTIC AGENT FOR TREATING HYPERLIPIDEMIA AND DISEASES RELATED TO HYPERLIPIDEMIA COMPRISING SAME - The present invention relates to apolipoprotein A-1 mimic peptides, and therapeutic agent for treating hyperlipidemia and diseases related to hyperlipidemia comprising the same. More specifically, the apolipoprotein A-1 mimic peptides of the present invention were manufactured by modifying hydrophilic or hydrophobic face of existing 4F amphipathic peptides to produce Apo A-I mimic peptides which specifically bind with cholesterol ester to allow high density lipoprotein content to increase, and the peptide of which phenylalanine in hydrophobic face of 4F is substituted with 2-naphthylalanine has superior cholesterol efflux capability and cognitive function for lipids to the existing 4F peptides, among the mimic peptides. Thus, the Apo A-I mimic peptides of the present invention can be used as Apo A-I mimic peptides and as a therapeutic agent for treating hyperlipidemia and diseases related to hyperlipidemia. | 2012-10-25 |
| 20120270772 | LIPOPEPTIDE COMPOSITIONS AND RELATED METHODS - The present disclosure provides novel powder daptomycin formulations which have improved chemical stability and faster reconstitution times when in the solid state. Some examples of the compositions comprise daptomycin and sucrose. | 2012-10-25 |
| 20120270773 | TRIM5ALPHA MUTANTS AND USES THEREOF - New mutant forms of TRIM5α comprising one or more mutations at amino acid positions corresponding to amino acids 324, 328, 330, 333, 335, 336 and/or 337 of wild-type human TRIM5α and which inhibit retrovirus replication are described. These mutants may be used, for example, in gene therapy applications for the prevention and/or treatment of retroviral infection and associated conditions, such as HIV-1 infection and AIDS. | 2012-10-25 |
| 20120270774 | MACROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND METHODS FOR PREVENTING OR TREATING HIV INFECTION - The present invention relates to backbone cyclized CD-4 mimetics and to compositions and methods comprising them for preventing and treating viral infection. In particular, the present invention relates to orally bio-available compounds and formulations for prevention and treatment of human HIV-1 infection. | 2012-10-25 |
| 20120270775 | CRYSTALLINE FORMS OF A POTENT HCV INHIBITOR - This invention relates to novel crystalline forms of the following Compound (1), and the sodium salt thereof, and methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of Hepatitis C Viral (HCV) infection: | 2012-10-25 |
| 20120270776 | NOVEL PESTICIDAL TOXINS - A novel pesticidal toxin that is highly active against a wide range of lepidopteran insect pests is disclosed. The DNA encoding the pesticidal toxin can be used to transform various prokaryotic and eukaryotic organisms to express the pesticidal toxin. These recombinant organisms can be used to control lepidopteran insects in various environments. | 2012-10-25 |
| 20120270777 | LACTOFERRIN AND GUT NEURONAL HEALTH IN ADULTS AND/OR ELDERLY - The present invention relates generally to the field of neuronal health and neuronal protection. One embodiment of the present invention relates to a composition that can be used for the protection of the enteric nervous system from neurodegeneration. Disorders linked to an impaired enteric nervous system can be treated or prevented by the administration of lactoferrin containing compositions according to the present invention. | 2012-10-25 |
| 20120270778 | Compositions and Methods for Non-Invasive Treatment of Chronic Complications of Diabetes - The present invention provides C-peptide compositions that permit the noninvasive or non-injectable administration of C-peptide via nasal or pulmonary routes, as well as methods for treating disease. | 2012-10-25 |
| 20120270779 | DOSING REGIMENS FOR NEURAL STEM CELL PROLIFERATING AGENTS AND DIFFERENTIATING AGENTS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS - Effective dosing regimens for neural stem cell proliferating and differentiating agents, kits comprising effective dosing regimens for neural stem cell proliferating and differentiating agents, and uses thereof are provided herein. Such kits and methods can be utilized acutely or chronically to treat a neurodegenerative disease or condition. Furthermore, the compositions and methods can be used continuously or intermittently in various dosing regimens. | 2012-10-25 |
| 20120270780 | METHOD AND COMPOSITION FOR MODULATING ERYTHROPOIESIS - The invention generally relates to compositions and methods of their use. More specifically, the invention relates to the use of a compound in modulating erythropoiesis in a subject by mediating the activity and/or quantity of a member present in the LPA | 2012-10-25 |
| 20120270781 | Expression Vectors and Cell Lines Expressing Vascular Endothelial Growth Factor D, and Method of Treating Melanomas - This invention relates to expression vectors comprising VEGF-D and its biologically active derivatives, cell lines stably expressing VEGF-D and its biologically active derivatives, and to a method of making a polypeptide using these expression vectors and host cells. The invention also relates to a method for treating and alleviating melanomas or tumors expressing VEGF-D and various diseases. | 2012-10-25 |
| 20120270782 | FORMULATION FOR HGH AND RHIGF-1 COMBINATION - The present invention relates to pharmaceutical compositions. More particularly, the invention relates to formulations of growth hormone (GH) and insulin-like growth factor (IGF-1) combination compositions which provide stable pharmaceutical compositions without aggregation formation at a desirable pH, and to processes of preparation thereof. | 2012-10-25 |
| 20120270783 | Rapid opioid detoxification - Rapid opioid detoxification procedures are provided which include sedating a patient with an anesthetic agent having a short full recovery period. The patient is administered an opioid antagonist while sedated and can be revived to an ambulatory condition within eight hours of initiating therapy. The described methods for detoxification also include administering a diarrhea suppressant, such as octreotide acetate, to limit this unfortunate side effect of the detoxification. | 2012-10-25 |
| 20120270784 | GROWTH HORMONE RELEASING FACTOR (GRF) ANALOGS AND USES THEREOF - Novel GRF analogs having GRF activity are described herein, as well as uses thereof for example as a GRF receptor agonist, e.g., to induce growth hormone secretion in a subject or biological system. | 2012-10-25 |
| 20120270785 | Therapy and Prevention of Problem Drinking - The present invention provides methods for the therapy and prevention of problem drinking in alcohol-dependent and non-dependent subjects and those at risk of developing problem drinking behavior, and compositions of matter comprising oxytocin or an analog or derivative thereof or an agonist or partial agonist of an oxytocin receptor that are useful in preventing or treating problem drinking. | 2012-10-25 |
| 20120270786 | INTESTINE AND MUSCLE RECOVERY - The present invention generally relates to the field of nutrition and health. In particular, the present invention provides a composition that allows it to treat, limit or prevent muscle atrophy. Embodiments of the present invention are directed at GLP-2 containing compositions and to compositions that stimulate the secretion of GLP-2 in a body to treat or prevent muscle atrophy. | 2012-10-25 |
| 20120270787 | COMPOUNDS HAVING PEPTIDES CONJUGATED TO BONE TARGETING MOIETIES AND METHODS OF MAKING AND USING THEREOF - Described herein are compositions having a peptide sequence that includes at least one bone targeting moiety, wherein the bone targeting moiety is bonded to the peptide sequence by a linker, wherein the peptide sequence is calcitonin, and wherein the composition is neutral or a pharmaceutically acceptable salt or ester thereof. In one aspect, calcitonin inhibits or slows osteoclast mediated resorptive bone loss. The compounds described herein can be used in a number of therapeutic applications including treating or preventing conditions associated with bone loss, which include, but are not limited to, osteoporosis, Paget's disease, osteolytic tumors, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Osteoarthritis, osteopenia, and hypercalcemia. Also described herein are the methods of making these compositions that prevent or treat conditions associated with bone loss and methods of preventing bone fractures. | 2012-10-25 |
| 20120270788 | Method of Administering Porcine B-Domainless fVIII - The present invention provides a method of administering porcine B-domainless factor VIII (OBI-1) to a patient having factor VIII deficiency to provide more rapid and effective protection against bleeding episodes, compared to formerly available methods, or to provide more effective protection to such patients during non-bleeding periods. This invention is based on the discovery that the recombinant B-domainless porcine fVIII, termed OBI-1, has greater bioavailability compared to the natural porcine fVIII partially purified from porcine plasma, termed HYATE:C. Therefore, the inventive method employs lower unit doses of OBI-1, including, alternatively, omission of antibody-neutralizing dosage, or has longer intervals between the administration, compared to HYATE:C, to provide equivalent protection in patients having fVIII deficiency. The invention further provides pharmaceutical compositions and kits containing OBI-1 in combination with a pharmaceutically acceptable carrier, that are useful for treating patients in need of fVIII more effectively. | 2012-10-25 |
| 20120270789 | TREATMENT OF COAGULOPATHY WITH HYPERFIBRINOLYSIS - The present invention relates to the use of thrombomodulin analogues for the manufacture of a medicament for the treatment of coagulopathy with hyperfibrinolysis, such as haemophilia disorders. These thrombomodulin analogs exhibit at therapeutically effective dosages an antifibrinolytic effect. Novel protein modifications together with methods for their identification are disclosed. | 2012-10-25 |
| 20120270790 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MYOCARDIAL ISCHEMIA/REPERFUSION INJURY WITH ANNEXIN A1 SHORT PEPTIDE - The present invention provides a method of treating, ameliorating or preventing myocardial ischemia/reperfusion injury in a subject in need thereof, by administering to the subject a therapeutically effective amount of an ANXA1short peptide (ANXA1sp). | 2012-10-25 |
| 20120270791 | Methods and Compositions for Treating and Diagnosing Kidney Disease - The invention relates to a method for diagnosing a kidney disease state. The method comprises the steps of administering to a patient a composition comprising a conjugate or complex of the general formula V-L-D where the group V comprises a vitamin receptor binding ligand that binds to kidney proximal tubule cells and the group D comprises a diagnostic marker, and diagnosing the kidney disease state. The invention also relates to a method for treating a kidney disease state. The method comprises the steps of administering to a patient suffering from the disease state an effective amount of a composition comprising a conjugate or complex of the general formula V-L-D where the group V comprises a vitamin receptor binding ligand that binds to kidney proximal tubule cells and the group D comprises an antigen, a cytotoxin, or a cell growth inhibitor, and eliminating the disease state. | 2012-10-25 |
| 20120270792 | UROCORTIN-III AND USES THEREOF - A search of the public human genome database identified a human EST, GenBank accession number AW293249, which has high homology to known pufferfish urocortin sequences. The full length sequence was amplified from human genomic DNA and sequenced. Sequence homology comparisons of the novel sequence with human urocortin I and urocortin II revealed that the sequence encoded a novel human urocortin, which was designated urocortin III (UcnIII). While urocortin III does not have high affinity for either CRF-R1 or CRF-R2, the affinity for CRF-R2 is greater than the affinity for CRF-R1. Urocortin III is capable stimulating cyclic AMP production in cells expressing CRF-R2α or β. Thus, the affinity is high enough that urocortin III could act as a native agonist of CRF-R2. However, it is also likely that urocortin III is a stronger agonist of a yet to be identified receptor. | 2012-10-25 |
| 20120270793 | METHODS OF TREATING A PATIENT RECEIVING A CARDIAC STENT IMPLANT - Methods of treating a patient receiving a cardiac stent implant including the steps of: (i) monitoring the circulating level of Tn I or CK-MB in the patient; and (ii) administering SERP-I to the patient in an amount sufficient to prevent the circulating level of Tn I or CK-MB from exceeding a specified threshold for the first 24 hours following implantation are disclosed. A specified value of SERP-I is sufficient for preventing circulating level of Tn I or CK-MB from exceeding a specified threshold during the first 24 hours following implantation. The dosing regime of SERP-I to the patient starting within 24 hours of post-implantation is also disclosed. | 2012-10-25 |
| 20120270794 | POLYMORPHISMS ASSOCIATED WITH PARKINSON'S DISEASE - The invention provides human polymorphisms that are associated with Parkinson's disease (PD). Also disclosed are compositions and methods for use in diagnostics, prognostics, prevention, treatment and/or study of PD. | 2012-10-25 |
| 20120270795 | COMPOUNDS FOR THE TREATMENT OF DISEASES RELATED TO PROTEIN MISFOLDING - The present invention relates to the field of protein misfolding diseases and thus to diseases which are associated with or induced by abnormal or pathogenic three-dimensional folding of proteins and/or peptides or which are linked to pathogenic conformational changes of proteins and/or peptides, such as Alzheimer's disease. Particularly, the present invention provides novel trimeric pyrazole compounds, which exhibit a therapeutic effectiveness in regard to the aforementioned protein misfolding diseases, and refers to their use for the treatment of such protein misfolding diseases, especially neurodegenerative diseases as well as to medicaments or pharmaceutical compositions comprising these compounds. | 2012-10-25 |
| 20120270796 | Suspension Type Topical Formulations Comprising Cyclic Depsipeptide - The invention relates to novel topical pharmaceutical compositions in which the active agent is a cyclic depsipeptide of formula (II) | 2012-10-25 |
| 20120270797 | ENGINEERED PROTEINS INCLUDING MUTANT FIBRONECTIN DOMAINS - The present invention features engineered proteins that can include a genetically modified Fn domain; two or more such domains joined to one another; or at least one genetically modified Fn domain joined to a target-specific protein scaffold. One or more accessory sequences can be included in or added to any of these configurations. Methods of use, including methods of treating cancer, with the engineered proteins are also disclosed. | 2012-10-25 |
| 20120270798 | Compositions and Methods for Preventing or Treating Cancer - The present invention relates to a MUC1 cytoplasmic tail peptide or portion thereof. These peptides are useful for inducing an immune response to MUC1-expressing tumor cells and thus for preventing or treating cancer. | 2012-10-25 |
| 20120270799 | METHOD OF IDENTIFYING A CANDIDATE COMPOUND WHICH MAY INHIBIT a9-nAchR OVEREXPRESSION OR ESTROGEN RECEPTOR-DEPENDENT TRANSCRIPTION IN NICOTINE-DERIVED-COMPOUND-INDUCED BREAST CANCER CELLS - The invention relates to methods of identifying a candidate compound which may inhibit estrogen receptor-dependent transcription or α9-nAChR overexpression and proliferation of nicotine-derived-compound-induced breast cancer cells by using an activating protein 1 (AP1) polypeptide. The invention found that α9-nAChR has an activating protein 1 (AP1)-binding site, that the α9-nAChR promoter is located at the AP1-binding site, and that ERs specifically bind to the α9-nAChR promoter at the AP1-binding site, indicating that ER-induced α9-nAChR up-regulation plays a central role in the response to endogenous (E2) or exogenous (nicotine) stimulation. | 2012-10-25 |
| 20120270800 | BIFUNCTIONAL STAPLED POLYPEPTIDES AND USES THEREOF - The invention relates to bifunctional stapled or stiched peptides comprising a targeting domain, a linker moiety, and an effector domain, that can be used to tether, or to bring into close proximity, at least two cellular entities (e.g., proteins). Certain aspects relate to bifunctional stapled or stiched peptides that bind to an effector biomolecule through the effector domain and bind to a target biomolecule through the targeting domain. Polypeptides and/or polypeptide complexes that are tethered by the bifunctional stapled or stiched peptides of the invention, where the effector polypeptide bound to the effector domain of the bifunctional stapled or stiched peptide modifies or alters the target polypeptide bound to the targeting domain of the bifunctional peptide. Uses of the inventive bifunctional stapled or stiched peptides including methods for treatment of disease (e.g., cancer, inflammatory diseases) are also provided. | 2012-10-25 |
| 20120270801 | HER3 BINDING POLYPEPTIDES - The disclosure provides a HER3 binding polypeptide, comprising a HER3 binding motif, BM, which motif consists of the amino acid sequence selected from i) EX | 2012-10-25 |
| 20120270802 | BINDING MOLECULES FOR THE TREATMENT OF MYELOID CELL MALIGNANCIES - Provided is a human C-type lectin, binding molecules that specifically bind to the human C-type lectin, nucleic acid molecules encoding the binding molecules or the human C-type lectin, compositions comprising the binding molecules or the human C-type lectin and methods of identifying or producing the binding molecules. The human C-type lectin is specifically expressed on myeloid cells and binding molecules capable of specifically binding to the human C-type lectin can be used in the diagnosis, prevention, and/or treatment of neoplastic disorders and diseases. | 2012-10-25 |
| 20120270803 | Mitotic Kinesin Inhibitors and Methods of Use Thereof - This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders. | 2012-10-25 |
| 20120270804 | METHODS FOR THE TREATMENT AND PREVENTION OF OCULAR DISORDERS - Provided herein are methods for treatment of ocular diseases. The methods comprise administering a compound of general Formula (I): wherein R | 2012-10-25 |
| 20120270805 | CYCLOSPORIN COMPOSITIONS - A composition is disclosed herein comprising from about 0.001% to about 0.4% cyclosporin A, castor oil, and a surfactant selected from the group consisting of alcohol ethoxylates, alcohols, alkyl glycosides, alkyl polyglycosides, alkylphenol ethoxylates, amine oxides, block polymers, carboxylated alcohol or alkylphenol ethoxylates, carboxylic acids/fatty acids, cellulose derivatives, ethoxylated alcohols, ethoxylated alkylphenols, ethoxylated aryl phenols, ethoxylated fatty acids, ethoxylated fatty acids, ethoxylated fatty esters and oils, fatty alcohols, fatty esters, glycol esters, lanolin-based derivatives, lecithin and lecithin derivatives, lignin and lignin derivatives, methyl esters, monoglycerides and derivatives, phosphalipids, polyacrylic acids, polyethylene glycols, polyethylene oxide-polypropylene oxide copolymers, polyethylene oxides, polymeric surfactants, polypropylene oxides, propoxylated alcohols, propoxylated alkyl phenols, propoxylated fatty acids, protein-based surfactants, sarcosine derivatives, silicone-based surfactants, sorbitan derivatives, stearates, sucrose and glucose esters and derivatives, and combinations thereof. | 2012-10-25 |
| 20120270806 | Designer Cyclic Peptides - HIV gp120 Antagonists and their Applications - The present invention is concerned with a novel composition of matter—a cyclic peptide derived from computer modeling studies that modulates the structure and function of the HIV main envelope protein gp120. The compound is capable of binding to the CD4-binding region of gp120 (this defines it as a CD4 mimic), and can be used for the purposes of: (1) controlling and preventing HIV infections, (2) detecting, isolating and purifying gp120. Contrary to examples of prior art that involved CD4 mimics being either small molecules or macromolecules, the present invention is concerned with the class of “large small molecules” that may offer a satisfactory balance between the activity and drug-like properties. Modified variants of the prototype compound that can be reasonably considered its derivatives are also claimed. | 2012-10-25 |
| 20120270807 | MACROCYCLIC INHIBITORS OF SERINE PROTEASE ENZYMES - The present invention relates to novel macrocyclic compounds and salts thereof that bind to and/or are inhibitors of serine protease enzymes. The present invention also relates to intermediates of these compounds, pharmaceutical compositions containing these compounds and methods of using the compounds. These compounds are useful as therapeutics for treatment and prevention of a range of disease indications including hyperproliferative disorders, in particular those characterized by tumor metastasis, inflammatory disorders, skin and tissue disorders, cardiovascular disorders, respiratory disorders and viral infections. | 2012-10-25 |
| 20120270808 | COMPOSITIONS AND METHODS RELATED TO SYNCHRONOUS SELECTION OF HOMING PEPTIDES FOR MULTIPLE TISSUES BY IN VIVO PHAGE DISPLAY - Embodiments of the invention include methods for selecting in parallel (i.e., synchronously or simultaneously) peptides that target a number of organs, in which each peptide targets distinct tissues or organs. Typically, the methods of the invention provide for peptide selection in a Minimal number of subjects and still provides a selectively binding peptide. In certain aspects, methods of identifying peptides that bind to multiple selected tissues or organs of an organism may comprise the steps of administering a phage display library to a first subject; obtaining a sample of two or more selected tissues; obtaining phage displaying peptides that bind to the samples from the first subject; enriching for peptides by administering phage isolated from the samples of the first subject to a second subject; obtaining a sample of two or more selected tissues from the second subject; and identifying the peptides displayed. | 2012-10-25 |
| 20120270809 | HUMAN TRANSMEMBRANE PROTEINS - The invention provides human transmembrane proteins (HTMPN) and polynucleotides which identify and encode HTMPN. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HTMPN. | 2012-10-25 |
| 20120270810 | MODIFICATION OF ENZYMATIC CROSSLINKERS FOR CONTROLLING PROPERTIES OF CROSSLINKED MATRICES - Improved matrix or hydrogel that is formed by enzymatic crosslinking of polymers wherein the crosslinking enzyme molecules have been modified for the purpose of improving the crosslinking density, mechanical properties, or other properties of the matrix, and/or to provide improved control over the rate and/or extent of crosslinking, wherein the enzyme molecules are modified to alter the perceived volume of the enzyme molecules in the crosslinked matrix being formed. Methods of production and of use are also provided. | 2012-10-25 |
| 20120270811 | CONFORMATIONS OF DIVERGENT PEPTIDES WITH MINERAL BINDING AFFINITY - A series of peptides with divergent confirmations including structures of formula (1A), (1B), (2) and (3) are provided. In the formula, wherein U, G, A, B, R1, R2 and T are as defined in the specification. The divergent peptides disclosed in the present invention are characterized in a mineral binding affinity function. | 2012-10-25 |
| 20120270812 | COMPOSITIONS, METHODS, AND KITS FOR DETERMINING AN ALKYL TRANSFERASE - The present invention relates to novel compounds as well as to compositions, methods, and kits comprising the compounds for determining an alkyltransferase (ATase), in particular an alkylguanine-DNA alkyl transferase (AGT). In general, the novel compounds provide for determining ATase levels, in particular for in vivo applications including, but not limited to, theranostic applications, in particular to cancer-related applications. | 2012-10-25 |
| 20120270813 | Process for Preparing Peptide Products for Promoting Cholecystokinin Secretion and Use of the Peptide Products - A process for producing a peptide product having cholecystokinin secretion promoting effect, said process comprising hydrolyzing soybean residues with one or more proteases so that the peptide product having cholecystokinin secretion promoting effect is obtained. Also disclosed is the composition containing the peptide product and the use thereof. | 2012-10-25 |
| 20120270814 | COMPOSITIONS AND METHODS FOR REDUCING OR PREVENTING OBESITY - Compositions useful for weight management in an animal are disclosed. The compositions comprise one or more isoflavones or isoflavone metabolites, and in some embodiments include conjugated linoleic acid, and/or L-carnitine. Also disclosed are methods useful for weight management in an animal utilizing compositions comprising one or more isoflavones, conjugated linoleic acid, and/or L-carnitine. Preferably, the compositions and methods employ a combination of one or more isoflavones, or a combination of one or more isoflavones in conjunction with conjugated linoleic acid, and L-carnitine. | 2012-10-25 |
| 20120270815 | MODIFIED-GALACTOSYL CERAMIDES FOR STAINING AND STIMULATING NATURAL KILLER T CELLS - Modified glycolipid compounds are provided. Also disclosed are methods for activating an NKT cell, methods of stimulating an immune response in a subject, and methods suitable for labeling NKT cells. | 2012-10-25 |
| 20120270816 | METHODS OF DIAGNOSING AND TREATING MIGRAINE - The present invention provides methods of diagnosing migraine attacks and determining predisposition of an individual to the development of migraine based on sodium level in the cerebrospinal fluid (CSF) and/or brain extracellular fluid. The invention also provides methods of treating migraine, wherein the individual is selected for treatment based in the individual's sodium level in the CSF and/or brain extracellular fluid. The CSF sodium level may be based on the sodium concentration in the saliva. | 2012-10-25 |
| 20120270817 | 6-Substituted Estradiol Derivatives and Methods of Use - A method of inhibiting growth of cancer cells comprising contacting cancer cells with a 6-substituted estradiol derivative in an amount at least partially sufficient to inhibit said growth is disclosed. The compounds have the general formula depicted below, wherein R | 2012-10-25 |
| 20120270818 | HDAC 6 INHIBITOR-BASED METHODS FOR TREATING CANCER - This invention provides methods for treating a subject afflicted with cancer, comprising concurrently administering (i) an HDAC 6-selective inhibitor and (ii) a suitable cytotoxic agent such as SAHA, doxorubicin or etoposide. This invention also provides methods for inducing the death of a transformed cell such as a cancer cell, comprising concurrently contacting the cell with (i) an HDAC 6-selective inhibitor and (ii) a suitable cytotoxic agent such as SAHA, doxorubicin or etoposide. | 2012-10-25 |
| 20120270819 | USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASE - Use of compounds with SGLT-1/SGLT-2 inhibitor activity for producing medicaments for treatment of bone diseases The invention relates to the use of compounds with SGLT-1/SGLT-2 inhibitor activity for producing medicaments for treatment of bone diseases like osteoporosis. Preferred is the use of compounds of the formula I in which the radicals have the stated meanings. | 2012-10-25 |
| 20120270820 | USE OF ALBIFLORIN FOR ANTI-DEPRESSION - A pharmaceutical composition containing albiflorin and use thereof in manufacturing medicaments for preventing and treating depression are provided by the present invention. | 2012-10-25 |
| 20120270821 | CDK5 Inhibitors and Therapeutic Uses Thereof - Natural occurring inhibitors of cyclin-dependent protein kinase 5 (Cdk5), isolated from the root of | 2012-10-25 |
| 20120270822 | STABILIZED FORMULATION FOR ORAL ADMINISTRATION OF THERAPEUTIC AGENTS AND RELATED METHODS - Stable formulations for the oral administration of therapeutic agents, methods for administering therapeutic agents using the formulations, and methods for treating conditions and diseases using the formulations. | 2012-10-25 |
| 20120270823 | AUREOLIC ACID DERIVATIVES, THE METHOD FOR PREPARATION THEREOF AND THE USES THEREOF - Aureolic acid derivatives, process for obtaining them and uses thereof. This invention provides a bacterial strain that produces compound belonging to the family of aureolic acids useful in the treatment of cancer or nervous system diseases. | 2012-10-25 |
| 20120270824 | MANNOSE DERIVATIVES AS ANTAGONISTS OF BACTERIAL ADHESION - Compounds of the formula (I) wherein n is 0, 1 or 2, R | 2012-10-25 |
| 20120270825 | SALIX EXTRACT, ITS USE AND FORMULATIONS CONTAINING IT - The present invention relates to an extract of | 2012-10-25 |
| 20120270826 | ADULT STEM CELLS, MOLECULAR SIGNATURES, AND APPLICATIONS IN THE EVALUATION, DIAGNOSIS, AND THERAPY OF MAMMALIAN CONDITIONS - The present invention relates to the identification of a stem cell-specific signature or signatures composed of protein and/or nucleic acid markers expressed by virtue of the position of a cell or cells in the time line of its/their development and the impact of the cells' environment on this signature as it relates to the cells' stem cell potential. The composition and combination of these signatures provides a means of identifying, manipulating and differentiating said adult stem cells and thus, their acquisition and utilization in research, diagnosis, and therapy of normal and pathological conditions. | 2012-10-25 |
| 20120270827 | Indole Antiviral Compositions And Methods - The present invention provides novel chemical compounds, and methods for their use. In particular, the present invention provides indole derivatives (e.g. as shown in Formula (I)) and related compounds and methods of using indole derivatives and related compounds as therapeutic agents to treat a number of conditions, including those associated with viral infection and cardiovascular diseases. | 2012-10-25 |
| 20120270828 | QUADRUPLE THERAPY USEFUL FOR TREATING PERSONS AFFLICTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS (HIV) - The present invention relates to a pharmaceutical composition for treating the human immunodeficiency virus (HIV) in a human being, comprising four active principles selected as being:
| 2012-10-25 |
| 20120270829 | USE OF ADENOSINE A3 RECEPTOR AGONISTS FOR TREATMENT OF NEUROPATHIC PAIN - A method of treating neuropathic pain in a subject is provided. The method comprises administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of an A | 2012-10-25 |
| 20120270830 | NUTRITIONAL COMPOSITIONS INCLUDING THEANINE AND EXOGENOUS NUCLEOTIDES - Nutritional compositions and methods of making and using the nutritional compositions are provided. In a general embodiment, the present disclosure provides a nutritional composition including theanine and one or more exogenous nucleotides. The nutritional compositions can be specifically used to treat functional bowel disorders, including inflammatory bowel syndrome. | 2012-10-25 |
| 20120270831 | METHOD FOR TREATING HEMATOPOIETIC NEOPLASMS - This invention relates to methods for treating a hematopoietic neoplasm comprising administering a therapeutically effective amount of a combretastatin compound, or a pharmaceutically acceptable salt thereof, to a subject having a hematological malignancy, wherein the combretastatin compound comprises a catechol or quinone moiety and is capable of forming a reactive oxygen species (ROS) in vivo. The method may further comprise co-administering a second chemotherapeutic agent. | 2012-10-25 |
| 20120270832 | KETONE ACCUMULATION INHIBITOR - A ketone body accumulation inhibitor that inhibits the accumulation of ketone bodies caused by exercising is provided in the present invention. The ketone body accumulation inhibitor contains isomaltulose as an active ingredient. | 2012-10-25 |
| 20120270833 | IMMUNE ACTIVATION OF GREEN TEA HYDROLYSATE AND METHOD FOR PREPARING FOOD COMPOSITION CONTAINING THE SAME - Disclosed are an immune-boosting food composition containing a green tea hydrolysate as an active component, and a method for preparing the same. | 2012-10-25 |
| 20120270834 | DEPOLYMERIZED GLYCOSAMINOGLYCAN FROM THELENOTA ANANAS AND PREPERATION METHOD THEREOF - Disclosed is a depolymerized glycosaminoglycan from | 2012-10-25 |
| 20120270835 | Medicinal Cream Made Using Hydrocortisone Acetate and A Process To Make The Same - The present invention relates to a composition for treating skin inflammation, along with skin rejuvenation. More particularly, the present invention relates to a pharmaceutical cream comprising a biopolymer, and a corticosteroid. It discloses a composition for treating skin inflammation, along with skin rejuvenation containing a) a biopolymer in the form of chitosan, b) an active pharmaceutical ingredient (API) composition in the form of hydrocortisone acetate, used in treating skin inflammation c) a cream base containing primary and secondary emulsifiers, waxy materials, co-solvents, acids, preservatives, buffering agents, anti oxidants, chelating agents, and humectants and d) water. The active ingredients, namely chitosan, and a corticosteroid in the form of hydrocortisone acetate, are incorporated in cream base for use in treating skin inflammation due to allergy & itching & wounds on human skin involving contacting human skin with the above identified composition. | 2012-10-25 |
| 20120270836 | THERAPEUTIC APPROACHES FOR TREATING ALZHEIMER'S DISEASE - The present invention relates to compositions and methods for the treatment of Alzheimer's disease and related disorders. More specifically, the present invention relates to novel combinatorial therapies of Alzheimer's disease and related disorders. In particular, the invention concerns compounds which, alone or in combination(s), can effectively modulate synapse function and/or angiogenesis and/or cell stress response. The invention also relates to methods of producing a drug or a drug combination for treating Alzheimer's disease and to methods of treating Alzheimer's disease or a related disorder. | 2012-10-25 |
| 20120270837 | COMPOSITIONS THAT TREAT OR INHIBIT PATHOLOGICAL CONDITIONS ASSOCIATED WITH INFLAMMATORY RESPONSE - A natural formulation of compounds that would to modulate inflammation is disclosed. The formulation would also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively in target cells. The compositions containing at least one fraction isolated or derived from hops. Other embodiments relate to combinations of components, including at least one fraction isolated or derived from hops, tryptanthrin and conjugates thereof, rosemary, an extract or compound derived from rosemary, a triterpene species, or a diterpene lactone or derivatives or conjugates thereof. | 2012-10-25 |
| 20120270838 | SPIROIMIDAZOLONE DERIVATIVE - The present invention relates to a compound represented by the following formula (1): | 2012-10-25 |
| 20120270839 | COMPOSITIONS AND METHODS FOR CANCER TREATMENT - Bromoacetoxycalcidiol (B3CD), which is structurally related to calcidiol, exhibits cytotoxic and apoptotic activity toward cancer cells, including highly aggressive neuroblastoma cells. A series of small molecules designed around the structure of B3CD is expected to have growth inhibitory and apoptogenic activities toward a wide range of malignancies. B3CD shows no apparent toxicity in vivo, indicating potential value as a chemotherapeutic agent which will be particularly useful in treating highly aggressive tumors. | 2012-10-25 |
| 20120270840 | Proteasome inhibitors and processes for their preparation, purification and use - The invention provides boronic esters of Formula I | 2012-10-25 |
| 20120270841 | Diazonamide Analogs - Diazonamide analogs having anti-mitotic activity, useful for the treatment of cancer and other proliferative disorders, and related pharmaceutical compositions are provided. | 2012-10-25 |
| 20120270842 | Inhibitors of Diacylglycerol O-Acyltransferase 1 (DGAT-1) and Uses Thereof - The invention pertains to use of DGAT-1 inhibitors to treat and/or prevent overweight, obesity and various diseases and disorders associated therewith. Other conditions also can be ameliorated or avoided, such as high postprandial triglycerides or diet-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance/glucose intolerance in overweight patients, those with diabetes or other glucose metabolic disorders such as Syndrome X and/or polycystic ovary disease. Compounds and compositions suitable for use in the disclosed methods are also provided. | 2012-10-25 |
| 20120270843 | PESTICIDE COMPOSITION COMPRISING PROPAMOCARB-FOSETYLATE AND AN INSECTICIDALLY ACTIVE SUBSTANCE - The present invention relates to a pesticide composition intended for protecting plants, crops or seeds against phyto-pathogenic fungi or damaging insects, and the corresponding methods of treatment using the said composition. More precisely, the subject of the present invention is a pesticide composition based on propamocarb-fosetylate, an insecticide active substance and optionally a further fungicide active substance. | 2012-10-25 |
